Strategic Partnerships Serina has actively pursued collaborations to advance their POZ Platform, notably with Gannet BioChem to enhance process development, scale-up, and manufacturing support for complex therapeutics. This collaboration signals openness to co-development and contract manufacturing opportunities that could fit a CDMO or bioprocessing partner interest.

Neuro & Pain Focus The company’s pipeline targets neurological diseases, pain, oncology, vaccines, and cannabinoid science, with recent emphasis on advanced Parkinson’s treatment. This presents cross-sell potential with suppliers or partners in neurology and pain management, as well as opportunities to license or co-develop POZ-based delivery systems for CNS therapies.

Funding Momentum With a total funding footprint of around $66M and multiple equity financings including $10M raised in early 2025, Serina demonstrates sustained investor interest and capital availability for strategic partnerships, clinical development, and scaling activities that buyers or investors could leverage for collaboration.

Technologies & IP Serina’s proprietary POZ Platform polymer technology underpins their drug delivery and formulation work, alongside UniverXome divestiture. This indicates a strong IP-backed value proposition that could attract partners seeking advanced delivery solutions or licensing opportunities for POZ-enabled programs.

Market Traction Active participation in investor conferences and a public-facing growth trajectory, including ongoing clinical development and a notable leadership transition with a new CEO, suggests the company is in a growth phase with potential needs for distribution, manufacturing scale-up, clinical operations support, and strategic advisory services.